H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients
Most oseltamivir-resistant pandemic (H1N1) 2009 viruses have been isolated from immunocompromised patients. To describe the clinical features, treatment, outcomes, and virologic data associated with infection from pandemic (H1N1) 2009 virus with H275Y mutation in immunocompromised patients, we retro...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centers for Disease Control and Prevention
2011-04-01
|
| Series: | Emerging Infectious Diseases |
| Subjects: | |
| Online Access: | https://wwwnc.cdc.gov/eid/article/17/4/10-1429_article |
| _version_ | 1818350504226324480 |
|---|---|
| author | Christian Renaud Alexandre A. Boudreault Jane Kuypers Kathryn H. Lofy Lawrence Corey Michael J. Boeckh Janet A. Englund |
| author_facet | Christian Renaud Alexandre A. Boudreault Jane Kuypers Kathryn H. Lofy Lawrence Corey Michael J. Boeckh Janet A. Englund |
| author_sort | Christian Renaud |
| collection | DOAJ |
| description | Most oseltamivir-resistant pandemic (H1N1) 2009 viruses have been isolated from immunocompromised patients. To describe the clinical features, treatment, outcomes, and virologic data associated with infection from pandemic (H1N1) 2009 virus with H275Y mutation in immunocompromised patients, we retrospectively identified 49 hematology–oncology patients infected with pandemic (H1N1) 2009 virus. Samples from 33 of those patients were tested for H275Y genotype by allele-specific real-time PCR. Of the 8 patients in whom H275Y mutations was identified, 1 had severe pneumonia; 3 had mild pneumonia with prolonged virus shedding; and 4 had upper respiratory tract infection, of whom 3 had prolonged virus shedding. All patients had received oseltamivir before the H275Y mutation was detected; 1 had received antiviral prophylaxis. Three patients excreted resistant virus for >60 days. Emergence of oseltamivir resistance is frequent in immunocompromised patients infected with pandemic (H1N1) 2009 virus and can be associated with a wide range of clinical disease and viral kinetics. |
| first_indexed | 2024-12-13T18:22:54Z |
| format | Article |
| id | doaj.art-64e25d4d740b42b7b037f21b43a38b0f |
| institution | Directory Open Access Journal |
| issn | 1080-6040 1080-6059 |
| language | English |
| last_indexed | 2024-12-13T18:22:54Z |
| publishDate | 2011-04-01 |
| publisher | Centers for Disease Control and Prevention |
| record_format | Article |
| series | Emerging Infectious Diseases |
| spelling | doaj.art-64e25d4d740b42b7b037f21b43a38b0f2022-12-21T23:35:40ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592011-04-0117465366010.3201/eid1704.101429H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised PatientsChristian RenaudAlexandre A. BoudreaultJane KuypersKathryn H. LofyLawrence CoreyMichael J. BoeckhJanet A. EnglundMost oseltamivir-resistant pandemic (H1N1) 2009 viruses have been isolated from immunocompromised patients. To describe the clinical features, treatment, outcomes, and virologic data associated with infection from pandemic (H1N1) 2009 virus with H275Y mutation in immunocompromised patients, we retrospectively identified 49 hematology–oncology patients infected with pandemic (H1N1) 2009 virus. Samples from 33 of those patients were tested for H275Y genotype by allele-specific real-time PCR. Of the 8 patients in whom H275Y mutations was identified, 1 had severe pneumonia; 3 had mild pneumonia with prolonged virus shedding; and 4 had upper respiratory tract infection, of whom 3 had prolonged virus shedding. All patients had received oseltamivir before the H275Y mutation was detected; 1 had received antiviral prophylaxis. Three patients excreted resistant virus for >60 days. Emergence of oseltamivir resistance is frequent in immunocompromised patients infected with pandemic (H1N1) 2009 virus and can be associated with a wide range of clinical disease and viral kinetics.https://wwwnc.cdc.gov/eid/article/17/4/10-1429_articleInfluenzaoseltamivirimmunocompromised hostdiagnosistreatment outcomeantiviral drug resistance |
| spellingShingle | Christian Renaud Alexandre A. Boudreault Jane Kuypers Kathryn H. Lofy Lawrence Corey Michael J. Boeckh Janet A. Englund H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients Emerging Infectious Diseases Influenza oseltamivir immunocompromised host diagnosis treatment outcome antiviral drug resistance |
| title | H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients |
| title_full | H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients |
| title_fullStr | H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients |
| title_full_unstemmed | H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients |
| title_short | H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients |
| title_sort | h275y mutant pandemic h1n1 2009 virus in immunocompromised patients |
| topic | Influenza oseltamivir immunocompromised host diagnosis treatment outcome antiviral drug resistance |
| url | https://wwwnc.cdc.gov/eid/article/17/4/10-1429_article |
| work_keys_str_mv | AT christianrenaud h275ymutantpandemich1n12009virusinimmunocompromisedpatients AT alexandreaboudreault h275ymutantpandemich1n12009virusinimmunocompromisedpatients AT janekuypers h275ymutantpandemich1n12009virusinimmunocompromisedpatients AT kathrynhlofy h275ymutantpandemich1n12009virusinimmunocompromisedpatients AT lawrencecorey h275ymutantpandemich1n12009virusinimmunocompromisedpatients AT michaeljboeckh h275ymutantpandemich1n12009virusinimmunocompromisedpatients AT janetaenglund h275ymutantpandemich1n12009virusinimmunocompromisedpatients |